
Brian A. Whiteman
Examiner (ID: 2464)
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1674, 1636, 1633 |
| Total Applications | 1737 |
| Issued Applications | 917 |
| Pending Applications | 262 |
| Abandoned Applications | 606 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18612669
[patent_doc_number] => 20230279402
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => Aptamers Specific for TLR-4 and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/156936
[patent_app_country] => US
[patent_app_date] => 2023-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22157
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156936
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156936 | Aptamers Specific for TLR-4 and Uses Thereof | Jan 18, 2023 | Pending |
Array
(
[id] => 18771163
[patent_doc_number] => 20230365974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/156177
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20845
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156177
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156177 | COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION | Jan 17, 2023 | Pending |
Array
(
[id] => 18771163
[patent_doc_number] => 20230365974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/156177
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20845
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156177
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156177 | COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION | Jan 17, 2023 | Pending |
Array
(
[id] => 18724290
[patent_doc_number] => 20230338424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 18/154209
[patent_app_country] => US
[patent_app_date] => 2023-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37701
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154209
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/154209 | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy | Jan 12, 2023 | Pending |
Array
(
[id] => 18724290
[patent_doc_number] => 20230338424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 18/154209
[patent_app_country] => US
[patent_app_date] => 2023-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37701
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154209
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/154209 | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy | Jan 12, 2023 | Pending |
Array
(
[id] => 18724290
[patent_doc_number] => 20230338424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 18/154209
[patent_app_country] => US
[patent_app_date] => 2023-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37701
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154209
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/154209 | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy | Jan 12, 2023 | Pending |
Array
(
[id] => 20116207
[patent_doc_number] => 12365899
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
[patent_app_type] => utility
[patent_app_number] => 18/145218
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 33
[patent_no_of_words] => 37464
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145218
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/145218 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Dec 21, 2022 | Issued |
Array
(
[id] => 18483588
[patent_doc_number] => 20230210887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7
MRNA FOR TREATING HEPATITIS B INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/145791
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39154
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145791
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/145791 | NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7 MRNA FOR TREATING HEPATITIS B INFECTION | Dec 21, 2022 | Pending |
Array
(
[id] => 18693015
[patent_doc_number] => 20230323396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEM
[patent_app_type] => utility
[patent_app_number] => 18/067686
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067686
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067686 | Tetracycline-inducible expression system | Dec 15, 2022 | Issued |
Array
(
[id] => 18693015
[patent_doc_number] => 20230323396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEM
[patent_app_type] => utility
[patent_app_number] => 18/067686
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067686
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067686 | Tetracycline-inducible expression system | Dec 15, 2022 | Issued |
Array
(
[id] => 20329938
[patent_doc_number] => 12460205
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Compositions and methods for treating alpha-1 antitrypsin deficiency
[patent_app_type] => utility
[patent_app_number] => 18/063817
[patent_app_country] => US
[patent_app_date] => 2022-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 27
[patent_no_of_words] => 25935
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063817
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063817 | Compositions and methods for treating alpha-1 antitrypsin deficiency | Dec 8, 2022 | Issued |
Array
(
[id] => 20329938
[patent_doc_number] => 12460205
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Compositions and methods for treating alpha-1 antitrypsin deficiency
[patent_app_type] => utility
[patent_app_number] => 18/063817
[patent_app_country] => US
[patent_app_date] => 2022-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 27
[patent_no_of_words] => 25935
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063817
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063817 | Compositions and methods for treating alpha-1 antitrypsin deficiency | Dec 8, 2022 | Issued |
Array
(
[id] => 19127532
[patent_doc_number] => 20240132885
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => MODULATION OF TRANSTHYRETIN EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/060965
[patent_app_country] => US
[patent_app_date] => 2022-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060965
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060965 | MODULATION OF TRANSTHYRETIN EXPRESSION | Dec 1, 2022 | Pending |
Array
(
[id] => 18970371
[patent_doc_number] => 20240050463
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B
[patent_app_type] => utility
[patent_app_number] => 18/071353
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49451
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18071353
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/071353 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | Nov 28, 2022 | Pending |
Array
(
[id] => 18597589
[patent_doc_number] => 20230272385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
[patent_app_type] => utility
[patent_app_number] => 17/993559
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993559
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/993559 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | Nov 22, 2022 | Pending |
Array
(
[id] => 18597589
[patent_doc_number] => 20230272385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
[patent_app_type] => utility
[patent_app_number] => 17/993559
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993559
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/993559 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | Nov 22, 2022 | Pending |
Array
(
[id] => 18597589
[patent_doc_number] => 20230272385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
[patent_app_type] => utility
[patent_app_number] => 17/993559
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993559
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/993559 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | Nov 22, 2022 | Pending |
Array
(
[id] => 18709540
[patent_doc_number] => 20230332159
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => MATERIALS AND METHODS FOR THE DELIVERY OF THERAPEUTIC NUCLEIC ACIDS TO TISSUES
[patent_app_type] => utility
[patent_app_number] => 17/985683
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12921
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17985683
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/985683 | MATERIALS AND METHODS FOR THE DELIVERY OF THERAPEUTIC NUCLEIC ACIDS TO TISSUES | Nov 10, 2022 | Abandoned |
Array
(
[id] => 18363032
[patent_doc_number] => 20230144623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY
[patent_app_type] => utility
[patent_app_number] => 18/054264
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054264
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054264 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | Nov 9, 2022 | Abandoned |
Array
(
[id] => 18326146
[patent_doc_number] => 20230124274
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => MICRORNA-BASED LOGIC GATES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/978490
[patent_app_country] => US
[patent_app_date] => 2022-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16164
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17978490
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/978490 | MicroRNA-based logic gates and uses thereof | Oct 31, 2022 | Issued |